Morgan Stanley
BCAX

Morgan Stanley’s Bicara Therapeutics BCAX Stock Holding History

Morgan Stanley’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.38M Buy
421,219
+311,763
+285% +$5.37M ﹤0.01% 3712
2025
Q4 		$1.84M Buy
109,456
+9,428
+9% +$161K ﹤0.01% 4868
2025
Q3 		$1.58M Sell
100,028
-104,432
-51% -$1.17M ﹤0.01% 4921
2025
Q2 		$1.9M Sell
204,460
-947,671
-82% -$11.3M ﹤0.01% 4732
2025
Q1 		$15M Buy
1,152,131
+749,213
+186% +$9.95M ﹤0.01% 2974
2024
Q4 		$7.02M Buy
402,918
+400,918
+20,046% +$8.34M ﹤0.01% 3699
2024
Q3 		$50.9K Buy
+2,000
New +$51K ﹤0.01% 6218

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Morgan Stanley's BCAX Position: Q1 2026 in Review

Morgan Stanley increased its Bicara Therapeutics (BCAX) stake by 285% in Q1 2026, buying an estimated $5.37M and bringing the position to 421,219 shares worth $8.38M. The position accounts for ﹤0.01% of the portfolio, ranked #3712.

Morgan Stanley first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. The position peaked at $15M in Q1 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Morgan Stanley held 421,219 shares of Bicara Therapeutics worth $8.38M as of Q1 2026.
  • Morgan Stanley bought 311,763 Bicara Therapeutics shares in Q1 2026, an estimated $5.37M.
  • Bicara Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #3712 holding.
  • Morgan Stanley first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Morgan Stanley's Bicara Therapeutics position peaked at $15M in Q1 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.